Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 4Stomach Neoplasms 3Triple Negative Breast Neoplasms 2Advanced Solid Tumor 2Advanced Cancer 2Solid Tumor, Adult 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1NSCLC 1Mouth Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Cytochrome P450 Interaction 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biliary Tract Malignancies 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × apatinib × Clear all
NCT03026881 2017-03-07

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Recurrence, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡